The Servier case: The game isn’t over yet – The European Court of Justice recently issued seven judgments in the landmark “Servier” case, confirming the anticompetitive nature of “pay-for-delay” agreements between originator and generic companies. However, the case is not fully resolved, as part of it was referred back to the General Court. This decision underscores the strict scrutiny of anticompetitive practices in the pharmaceutical industry and its impact on market strategies….
By: Dechert LLP



Source link